Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

High-Density Fed-Batch Optimization Cuts GLP-1 Bioproduction Costs

Researchers in India have developed a high-density fermentation strategy that significantly increases the yields of recombinant glucagon-like peptides-1 (GLP-1) in Escherichia coli. It may reduce upstream production costs by 20–30%. U.S. governmental policy ch

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers in India have developed a high-density fermentation strategy that significantly increases the yields of recombinant glucagon-like peptides-1 (GLP-1) in Escherichia coli. It may reduce upstream production costs by 20–30%.

U.S. governmental policy changes are expected to lower GLP-1 costs to payers from their list prices of $1,000 or more per month to about $350 per month this year, and future products targeted at $149 per month. That price drop cuts into profit margins, leaving biomanufacturers eager to identify increasingly efficient bioproduction methods despite projected market expansions.

In a recent paper from Guru Gobind Singh Indraprastha University, Sushmita R. Kumar, student; Esha Shukla, research scientist, now with Techinvention Lifecare; and Gaurav Pandey, PhD, associate professor, engineered expression constructs that encoded monomeric GLP-1 fused to glutathione S-transferases (GST). After a 26-hour fermentation cycle, they achieved “the highest volumetric yield reported to date for GLP-1 in the E. coli expression system,” they reported.

High-density E. coli production

Specifically, the team optimized high-density fed-batch bioprocessing to produce a volumetric yield of 10.3 g/L with an optical density of 180, as well as the highest volumetric production for a soluble rGLP-1 analog, of 0.4 g/L/h. The specific yield was 116.7 mg/g, and the dry cell weight was 88.9 g/L.

To achieve such yields, the team optimized the system specifically to increase soluble expression of rGLP-1. They divided the work into two stages: optimizing the inducer concentration, pH, and harvest time, followed by optimizing fermentation temperature.

For the first stage, they found that 0.5 mM inducer, pH 7, and an eight-hour post-induction harvest time were optimal.

For the second stage, they reported that by lowering the fermentation temperature to 25° C—well below the more typical 37°C—increased protein yields and minimized the acetate accumulation. This approach delayed the initial feeding by four hours, but appears to have compensated by shifting excess carbon to growth-inducing pathways. Then, when feeding began, cells experienced a higher growth rate than has been reported in the literature, enabling them to produce more recombinant protein.

Pandey and colleagues say this feeding strategy may be applied to other recombinant peptides expressed in E. coli.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →